Oxaprozin versus aspirin in rheumatoid arthritis: a double-blind trial

Publisher Website
Google Scholar
Abstract
A parallel double-blind trial was carried out over a 3-month period in 40 patients suffering from active rheumatoid arthritis to compare the anti-inflammatory effectiveness and side-effects of treatment with oxaprozin and aspirin. The results showed that 1200 mg oxaprozin daily had similar anti-inflammatory properties to those of 3.9 g aspirin daily in rheumatoid arthritis. Better results were produced with 1200 mg oxaproxin daily than with a 600 mg dosage level, suggesting that there is a close dose-response relationship. The incidence of side-effects was similar with both drugs. Gastrointestinal intolerance was more frequent and severe in the aspirin group, whereas rash and headache were noted more often in patients receiving oxaprozin.

This publication has 1 reference indexed in Scilit: